Nocebo effects with antidepressant clinical drug trial placebos

2007 ◽  
Vol 29 (3) ◽  
pp. 275-277 ◽  
Author(s):  
Roy R. Reeves ◽  
Mark E. Ladner ◽  
Roy H. Hart ◽  
Randy S. Burke
Keyword(s):  
Drug Trial ◽  
Clinical Drug Trial ◽  
Nocebo Effects ◽  
Clinical Drug

scholarly journals Perception of various stakeholders regarding clinical drug trial industry in India

2011 ◽  
Vol 2 (3) ◽  
pp. 86
Author(s):  
RakeshM Parikh ◽  
Mahesh Goyal ◽  
MS Dolima ◽  
Kirti Pandia ◽  
Meenakshi Sharma
Keyword(s):  
Drug Trial ◽  
Clinical Drug Trial ◽  
Clinical Drug

Understanding and preparing for clinical drug trial audits

2002 ◽  
Vol 59 (23) ◽  
pp. 2301-2301 ◽  
Author(s):  
Rivka Siden ◽  
Roberta M. Tankanow ◽  
Helen R. Tamer
Keyword(s):  
Drug Trial ◽  
Clinical Drug Trial ◽  
Clinical Drug

scholarly journals Plasmodium vivax Polymorphism in a Clinical Drug Trial

2001 ◽  
Vol 8 (5) ◽  
pp. 891-894 ◽  
Author(s):  
T. Adak ◽  
Neena Valecha ◽  
V. P. Sharma
Keyword(s):  
Plasmodium Vivax ◽  
Drug Response ◽  
Drug Trial ◽  
Short Term ◽  
Double Blind ◽  
Response Data ◽  
Clinical Drug Trial ◽  
Clinical Drug

ABSTRACT Data from a double-blind randomized clinical drug trial were analyzed to find the comparative responses of two antirelapse drugs, bulaquine and primaquine, against different relapsing forms ofPlasmodium vivax infection. A 1-year follow-up study strongly suggests that the duration of preerythrocytic development ofP. vivax is a polymorphic characteristic, exhibited by two strains of hypnozoites responsible for early and late manifestations after primary infection. Short-term relapses were significantly higher in the first half year than long-term relapses, and the reverse was true in the second half year. Clinical drug response data showed that the hypnozoites characterized for short-term relapse were not susceptible to either of the antirelapse drugs in the currently administered dose, whereas hypnozoites characterized for long incubation were significantly susceptible.

Functional Brain Imaging for Pain: A Clinical Drug Trial

2012 ◽  
Vol 114 (3) ◽  
pp. e60
Author(s):  
S. Scrivani ◽  
E. Moulton ◽  
A. Wasan ◽  
Z. Bajwa ◽  
L. Becerra ◽  
...  
Keyword(s):  
Brain Imaging ◽  
Functional Brain Imaging ◽  
Drug Trial ◽  
Functional Brain ◽  
Clinical Drug Trial ◽  
Clinical Drug

Lessons Learnt in Conducting a Clinical Drug Trial in Children with Asperger Syndrome

2005 ◽  
Vol 13 (2) ◽  
pp. 173-175 ◽  
Author(s):  
John Mathai ◽  
Angela Bourne ◽  
Noel Cranswick
Keyword(s):  
Clinical Trial ◽  
Clinical Pharmacology ◽  
Asperger Syndrome ◽  
Drug Trial ◽  
Major Barrier ◽  
Clinical Drug Trial ◽  
Lessons Learnt ◽  
Main Barrier ◽  
Clinical Drug

Objective: To describe the authors' experience of conducting a clinical drug trial in children with Asperger Syndrome, including the pitfalls encountered and lessons learnt. Conclusions: The main barrier encountered was in the recruitment of children: it was not possible to recruit the target of 60 patients. The recruitment of children is often the major barrier to the progress of a successful clinical trial. Conducting the clinical drug trial was greatly facilitated by the appropriate setting and experienced clinical pharmacology staff.

Sign in / Sign up

Export Citation Format

Share Document